menu
    • menu

    Company profile for Indapta Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Indapta is a biotechnology company seeking to harness the natural power of the immune system to fight hematologic and solid cancers with our universal G-NK cell platform. Headquartered in San Francisco, Indapta was founded in 2017 by Guy DiPierro along with Ronald Martell and scientists at the University of California, Davis, and Stanford University. The company has developed allogeneic FcRγ-deficient natural killer cells, kn...
    Indapta is a biotechnology company seeking to harness the natural power of the immune system to fight hematologic and solid cancers with our universal G-NK cell platform. Headquartered in San Francisco, Indapta was founded in 2017 by Guy DiPierro along with Ronald Martell and scientists at the University of California, Davis, and Stanford University. The company has developed allogeneic FcRγ-deficient natural killer cells, known as G-NK cells. Indapta is working to bring this off-the-shelf cellular therapy to cancer patients to address the limitations of currently available immunotherapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Indapta TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Francisco, CA
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://indapta.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Indapta Shows Allogeneic Nk Cell Therapy Efficacy
    Indapta Shows Allogeneic Nk Cell Therapy Efficacy

    07 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251107598785/en/Indapta-Therapeutics-Presents-Data-Demonstrating-Clinical-Activity-of-its-Allogeneic-Natural-Killer-Cell-Therapy-in-Patients-with-RelapsedRefractory-Multiple-Myeloma

    BUSINESSWIRE
    07 Nov 2025
    Share Share
    Indapta Secures $22.5M for Cancer & Autoimmune Clinical Trials
    Indapta Secures $22.5M for Cancer & Autoimmune Clinical Trials

    17 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241217242473/en

    BUSINESSWIRE
    17 Dec 2024
    Share Share
    Indapta Partners with Sanofi on Multiple Myeloma Program
    Indapta Partners with Sanofi on Multiple Myeloma Program

    06 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241206163453/en

    BUSINESSWIRE
    06 Dec 2024
    Share Share
    Indapta Presents NK Cell Therapy Data at SITC 2024
    Indapta Presents NK Cell Therapy Data at SITC 2024

    07 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241107081017/en

    BUSINESSWIRE
    07 Nov 2024
    Share Share
    Indapta G-Nk Plenary Featured: Nyas Cancer Immunotherapy Conference
    Indapta G-Nk Plenary Featured: Nyas Cancer Immunotherapy Conference

    23 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240523971970/en

    BUSINESSWIRE
    23 May 2024
    Share Share
    Indapta Awarded $4.5M By CPRIT For NK Cell Therapy
    Indapta Awarded $4.5M By CPRIT For NK Cell Therapy

    21 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240521592452/en

    BUSINESSWIRE
    21 May 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search